Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06446154

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

Fruquintinib in Patients With Unresectable Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors : A Single-arm, Phase II Study

Sponsor: Guangzhou First People's Hospital

Conditions Anti-angiogenic Therapy Hepatocellular Carcinoma Immune Checkpoint Inhibitors Second-line Treatment

Interventions Fruquintinib

Updated 4 times since 2024 Last updated: Dec 29, 2024 Started: Dec 27, 2024 Primary completion: Dec 1, 2025 Completion: Jul 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anti-angiogenic Therapy and Hepatocellular Carcinoma and is currently actively recruiting participants. Guangzhou First People's Hospital leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou First People's Hospital
Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China